Vor Biopharma IncNASDAQ:VORNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8321
- TODAY'S CHANGE (%)0.0407 (5.1428%)
- Bid / Lots0.8100/ 5
- Ask / Lots0.8320/ 1
- Open / Previous Close0.8100 / 0.7914
- Day Range
- 52 Week Range
- Volume216,445
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VOR |
|---|---|---|
| 09:32 ET | 18347 | 0.7907 |
| 09:35 ET | 3917 | 0.798 |
| 09:37 ET | 8737 | 0.7951 |
| 09:39 ET | 100 | 0.80989 |
| 09:46 ET | 1170 | 0.8 |
| 09:48 ET | 2036 | 0.7952 |
| 09:51 ET | 729 | 0.7952 |
| 09:55 ET | 200 | 0.80255 |
| 09:57 ET | 300 | 0.8007 |
| 10:02 ET | 10263 | 0.8199 |
| 10:04 ET | 10561 | 0.816399 |
| 10:06 ET | 4100 | 0.8163 |
| 10:11 ET | 400 | 0.8101 |
| 10:15 ET | 251 | 0.8132 |
| 10:20 ET | 4300 | 0.8101 |
| 10:24 ET | 5300 | 0.8162 |
| 10:27 ET | 1041 | 0.8132 |
| 10:29 ET | 125 | 0.8119 |
| 10:33 ET | 19700 | 0.811672 |
| 10:36 ET | 100 | 0.8163 |
| 10:45 ET | 2100 | 0.8101 |
| 10:47 ET | 1130 | 0.8186 |
| 10:49 ET | 190 | 0.81865 |
| 10:51 ET | 12859 | 0.8273 |
| 10:56 ET | 2530 | 0.834 |
| 10:58 ET | 1260 | 0.834 |
| 11:00 ET | 2086 | 0.834 |
| 11:02 ET | 100 | 0.834 |
| 11:03 ET | 5311 | 0.8346 |
| 11:05 ET | 7283 | 0.822874 |
| 11:07 ET | 300 | 0.83 |
| 11:09 ET | 100 | 0.8207 |
| 11:12 ET | 500 | 0.82535 |
| 11:14 ET | 100 | 0.8207 |
| 11:18 ET | 2128 | 0.8104 |
| 11:32 ET | 598 | 0.8181 |
| 11:38 ET | 5899 | 0.8279 |
| 11:41 ET | 2544 | 0.825941 |
| 11:43 ET | 100 | 0.814 |
| 11:50 ET | 100 | 0.82065 |
| 11:52 ET | 154 | 0.8278 |
| 11:54 ET | 250 | 0.8277 |
| 12:08 ET | 1300 | 0.8201 |
| 12:10 ET | 200 | 0.8201 |
| 12:12 ET | 758 | 0.82122 |
| 12:14 ET | 334 | 0.8278 |
| 12:15 ET | 8300 | 0.8286 |
| 12:17 ET | 1717 | 0.8248 |
| 12:19 ET | 500 | 0.8201 |
| 12:21 ET | 100 | 0.8201 |
| 12:26 ET | 1125 | 0.8201 |
| 12:32 ET | 1100 | 0.8201 |
| 12:35 ET | 1499 | 0.8201 |
| 12:48 ET | 17089 | 0.835 |
| 12:50 ET | 5363 | 0.8253 |
| 12:51 ET | 4801 | 0.8253 |
| 01:00 ET | 3277 | 0.8321 |
Nov 12, 2024
Vor Bio to Participate in the Stifel 2024 Healthcare Conference, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
DJ Vor Biopharma Is Maintained at Outperform by Baird, from 7:40AM ET on Friday Nov 08, 2024 by Dow Jones
7:40AM ET on Friday Nov 08, 2024 by Dow JonesDJ Vor Biopharma Price Target Maintained With a $17.50/Share by HC Wainwright & Co., from 6:22AM ET on Friday Nov 08, 2024 by Dow Jones
6:22AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Press Release: Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow JonesVor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vor Biopharma Inc | 54.9M | -0.5x | --- |
Maia Biotechnology Inc | 55.2M | -1.6x | --- |
Elicio Therapeutics Inc | 54.5M | -1.0x | --- |
Immix Biopharma Inc | 54.2M | -2.5x | --- |
Iterum Therapeutics PLC | 55.9M | -1.0x | --- |
Prelude Therapeutics Inc | 53.9M | -0.6x | --- |
Company Information
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Contact Information
- Headquarters
- 100 Cambridgepark Drive, Suite 101CAMBRIDGE, MA, United States 02140
- Phone
- 617-655-6580
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Matthew Patterson
- President, Chief Executive Officer, Director
- Robert Ang
- Chief Financial Officer
- Han Choi
- Chief Scientific Officer
- Tirtha Chakraborty
- Chief Medical Officer
- Eyal Attar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 68.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.40 |
EPS | $-1.65 |
Book Value | $2.22 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
